Background Immunotherapy has revolutionized cancer treatment, but most patients are
refractory to immunotherapy or acquire resistance, with the underlying mechanisms …

Background Neoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC)
has improved pathological responses and survival rates compared with chemotherapy …

Multiple primary lung cancer (MPLC) remains a tough challenge to diagnose and treat.
Although neoadjuvant immunotherapy has shown promising results in early stage non-small …

Background Malignant transformation and progression of cancer are driven by the co-
evolution of cancer cells and their dysregulated tumor microenvironment (TME). Recent …

A thorough interrogation of the immune landscape is crucial for immunotherapy strategy
selection and prediction of clinical responses in non-small-cell lung cancer (NSCLC) …

Background Conventional immunohistochemistry technologies were limited by the inability
to simultaneously detect multiple markers and the lack of identifying spatial relationships …

Background Tumor-associated macrophages (TAMs) having immunosuppressive properties
are one of the most abundant immune cells in the tumor microenvironment (TME) …

Background Neoadjuvant immunotherapy is emerging as novel effective intervention in lung
cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is …

The composition and activation status of the cellular milieu contained within the tumour
microenvironment (TME) is becoming increasingly recognized as a driving factor for …

Immunotherapy has emerged as a promising approach to treat cancer. However, partial
responses across multiple clinical trials support the significance of characterizing intertumor …